Articles by Eric Donnenfeld, MD
Novel agents in the pipeline for DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Agents in the pipeline for DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Overlapping diseases and COVID-19's impact
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Counseling and formulary concerns for DED therapies
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Challenges in the management of DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Treatments for aqueous dry eye
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
In-office procedures and patient resistance for DED treatments
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
How to treat meibomian gland dysfunction
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
The role of nutritional supplements and antibiotics in DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Corticosteroids and Immunomodulators for the treatment of dry eye
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Review of artificial tears for DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
OD and MD communication for optimal care
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
General Principles of Treatment of DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Standard testing and assessment for DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Diagnosis and overlooking asymptomatic patients with DED
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Consequences and epidemiology of untreated dry eye
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Introduction and overview
ByBrooke Henson, Editor,Tracy Schroeder Swartz, OD, MS, FAAO,Marguerite McDonald, MD,Eric Donnenfeld, MD,Crystal Brimer, OD, FAAO 
Why comanagement matters
Surgical therapy for dry eye disease
Surgical therapy’s role in dry eye disease
Counseling and formulary concerns for DED therapies
General Principles of Treatment of DED
Novel agents in the pipeline for DED
.png "Optometry Times"){kind=logo}
